Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)
China · Delayed Price · Currency is CNY 5.72
+0.08 (1.42%)
Jul 30, 2026, 3:00 PM CST
SHA:605199 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 710.14 | 900.84 | 1,414 | 1,795 | 1,515 | 1,354 |
Revenue Growth | -44.51% | -36.27% | -21.26% | 18.49% | 11.91% | 16.54% |
Gross Profit Gross Profit Growth | 149.27 | 244.63 | 669.02 | 902.33 | 870.74 | 807.25 |
Operating Income Operating Income Growth | -287.25 | -239.36 | -246.27 | 21.74 | 97.52 | 72.7 |
Net Income Net Income Growth | -340.68 | -287.37 | -274.46 | 10.85 | 85.68 | 72.14 |
Earnings Per Share EPS Growth | -0.85 | -0.72 | -0.69 | 0.03 | 0.21 | 0.18 |
EPS Growth | - | - | - | -85.71% | 16.67% | -43.75% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Respiratory System Medication Respiratory System Medication Growth | 562.91 |
Digestive System Medicine Digestive System Medicine Growth | 139.72 |
Anti-infective Drugs Anti-infective Drugs Growth | 92.11 |
Other Medicines Other Medicines Growth | 60.75 |
Active Pharmaceutical Ingredient (api) Active Pharmaceutical Ingredient (api) Growth | 45.34 |
Total Total Growth | 900.84 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 76.57 | 78.21 | 254.29 | 522.69 | 480.37 | 487.68 |
Total Debt Total Debt Growth | 1,182 | 1,216 | 1,399 | 1,282 | 683.98 | 499.21 |
Net Cash (Debt) Net Cash Growth | -1,105 | -1,138 | -1,145 | -758.92 | -203.61 | -11.53 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -2.75 | -2.85 | -2.88 | -2.10 | -0.50 | -0.03 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 297.36 | 136.85 | -149.12 | 28.25 | 238.71 | 102.48 |
Capital Expenditures CapEx Growth | -52.07 | -83.67 | -156.23 | -489.2 | -392.32 | -137.62 |
Free Cash Flow Free Cash Flow Growth | 245.29 | 53.18 | -305.35 | -460.95 | -153.61 | -35.14 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 21.02% | 27.16% | 47.33% | 50.26% | 57.47% | 59.63% |
Operating Margin | -40.45% | -26.57% | -17.42% | 1.21% | 6.44% | 5.37% |
Pretax Margin | -45.13% | -29.82% | -19.04% | 1.51% | 6.42% | 6.03% |
Profit Margin | -47.97% | -31.90% | -19.42% | 0.60% | 5.66% | 5.33% |
FCF Margin | 34.54% | 5.90% | -21.60% | -25.68% | -10.14% | -2.60% |
| Fiscal Year | FY 2023 |
|---|---|
| Period Ending | Dec '23 Dec 31, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.125 |
Dividend Per Share Growth | - |
Dividend Yield | 0.83% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 558.97 | 74.81 | 138.22 |
P/FCF Ratio | 9.33 | 57.33 | - | - | - | - |
PS Ratio | 3.22 | 3.38 | 4.51 | 3.38 | 4.23 | 7.37 |